We were hosted to a site visit to four of First REIT’s hospitals in Jakarta by Management. All the hospitals we visited are operated by Siloam Hospitals (SILO IJ), a subsidiary of First REIT’s sponsor Lippo Karawaci and listed on Jakarta stock exchange. Below are our key takeaways from the visit.
State of the art equipment in Siloam Hospitals
To cater the middle-upper class of Indonesia, Siloam Hospitals (Siloam) boast of some of the most advanced medical equipment in the country. Since its founding, Siloam has been a pioneer in rolling out the latest technology in healthcare in Indonesia, such as in the use of MRI 3-Tesla, CT Scan 256 Slice, Rapid Arc Linear Accelerator and Gamma Knife. Siloam Lippo Village, for instance, houses the only Gamma Knife facility in the whole country (Figures 7 and 8). Gamma Knife is an advanced non-invasive radiation treatment for brain tumours and lesions.
Nationwide healthcare insurance BPJS driving healthcare demand in Indonesia
Jump in revenue from BPJS. For FY16, patients from BPJS Kesehatan (BPJS) contributed 20% (FY15: 5-7%) of total Gross Operating Revenue for Siloam Hospitals, despite having only 16 out of 23 operational hospitals participating in the scheme.
Nationwide coverage by 2019. Currently, about 170mn citizens are enrolled in BPJS Health. The scheme is expected to cover all Indonesian citizens by 2019. By 2019, all hospitals in Indonesia (including private ones) are mandated to accept BPJS patients, with a regulation to allocate at least 20% of rooms to Class 3 wards.
Affordable insurance premium payment for BPJS – Poor: Fixed premiums of IDR 19,225 paid by the government. Civil Servants/Private sector: 5% of salary, of which 4% to be paid by the employer (max Rp189,000) and 1% by employee (max Rp47,250).
Potential demand from private healthcare insurance. Indonesia’s private healthcare insurance penetration is estimated at 8% or roughly 20 million people1. With a growing middle class, there remains huge potential for private health insurance coverage to be expanded, which would drive demand for healthcare.
Rapid expansion in hospital assets in Indonesia – Overcoming the shortage of doctors in Indonesia
With a low number of doctors per 1,000 population of 0.3 in 2012, Indonesia has a significantly lower ratio of doctors than neighbouring Thailand (0.7), Malaysia (1.3) and Singapore (2.0). Only local doctors are allowed to practise in Indonesia. Lippo Group’s Universitas Pelita Harapan (UPH) has its own medical faculty where it trains doctors who will work in Siloam hospitals upon graduation. Except for new doctors on fixed pay, most other doctors are non-resident doctors with a profit-sharing remuneration system with the hospitals they work at. Doctors in Indonesia are allowed to practice at maximum 3 different hospitals. There are no regulations in Indonesia restricting the pricing of medical services.
Acquisition of Siloam Hospitals Yogyakarta
Separately, on 15 October 2017, First REIT announced the acquisition of the hospital component of an integrated development in Yogyakarta (Siloam Hospitals Yogyakarta) for S$27mn. Rental yield based on an initial base rent of S$2.43mn per annum is 9%, in line with previous acquisitions, and higher than the blended average cost of capital of c.5.1% (using an assumed 60-40% equity-debt ratio). The terms and quantum of the acquisitions are within our forecasts. This brings total acquisition quantum for the year to S$57mn.
1Source: Frost and Sullivan, 2016
Investment Action
We maintain our NEUTRAL rating on First REIT. Our unchanged target price of S$1.32 translates to an FY17e yield of 6.5% and P/NAV of 1.21.
First REIT Historical Dividend Yield and Price/NAV
Peer Comparison Table
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
Dehong covers primarily the REITs and property developer sector. He has close to 7 years experience in equities related dealing and research roles.
He graduated with a Masters of Science in Applied Finance from SMU and Bachelors of Accountancy from NTU.